RxDoctor Payments Data

Chard Bubb, MD

Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1902097215

Payments from drug & device makers

$636in general payments, 2019–2025

Across 21 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$158
  • Recordati_rare_diseases_inc.$121
  • Dexcom, Inc.$110
  • Insulet Corporation$96
  • Novo Nordisk$44
  • Medtronic$40
  • plus $67 from 3 others

What the payments were for

  • Food & beverage$636100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$636 in reported general payments places this provider in the 15th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.

See all endocrinology, diabetes & metabolism providers in Nevada

Medicare billing

Part B allowed, 2024
$58,103
Medicare patients
147
Services billed
1,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide214$323,670
JardianceEmpagliflozin209$254,389
OzempicSemaglutide162$244,885
TrulicityDulaglutide167$231,754
ProliaDenosumab61$107,638
Tresiba Flextouch U-100Insulin Degludec104$80,436
JanuviaSitagliptin Phosphate54$48,457
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog66$41,941
Novolog FlexpenInsulin Aspart92$31,352
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/725$29,806
Lantus SolostarInsulin Glargine,hum.Rec.Anlog155$27,705
RybelsusSemaglutide19$27,312
Humalog Kwikpen U-100Insulin Lispro58$22,574
FarxigaDapagliflozin Propanediol21$20,832
Soliqua 100-33Insulin Glargine/Lixisenatide13$19,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$44$285,620230 claims
AmgenProlia$16$107,63861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.

Other endocrinology, diabetes & metabolism in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →